LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus

Victoria P. Werth, Shimon Korish, Joerg Wenzel et al.|Unknown|2023

Cited by 0